# A Phase 1 TP-271 Oral PK Single Ascending Dose Study

> **NCT03024034** · PHASE1 · COMPLETED · sponsor: **Tetraphase Pharmaceuticals, Inc** · enrollment: 56 (actual)

## Conditions studied

- Bacterial Infections

## Interventions

- **DRUG:** TP-271

## Key facts

- **NCT ID:** NCT03024034
- **Lead sponsor:** Tetraphase Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-02
- **Primary completion:** 2017-12-01
- **Final completion:** 2018-06-04
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2021-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03024034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03024034, "A Phase 1 TP-271 Oral PK Single Ascending Dose Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03024034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*